Welcome to our dedicated page for Matinas Biopharm SEC filings (Ticker: MTNB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Matinas BioPharma Holdings, Inc. filings document a clinical-stage biopharmaceutical issuer built around lipid nanocrystal delivery technology and MAT2203, its oral amphotericin B antifungal candidate. Regulatory disclosures include material-event reports, proxy matters, governance changes, capital-structure actions, and public-company compliance items.
Recent MTNB filings cover NYSE American continued-listing notices, board and officer changes, executive compensation arrangements, warrant exchanges, authorized-share amendments, stockholder meeting results, and equity incentive plan approvals. These records also disclose the company’s common-stock structure, voting matters, risk-related listing issues, and formal reporting obligations as a public biotechnology company.
Matinas BioPharma Holdings, Inc. entered into Warrant Exchange Agreements with certain holders of warrants to purchase an aggregate of 466,666 shares of its common stock, each warrant having a current exercise price of $17.50. On August 15, 2025, the company completed an exchange in which it issued one share of common stock for each warrant, resulting in 466,666 new common shares being issued. The exchanged warrants, originally issued on April 5, 2024, were cancelled so that no further shares are issuable under them. The common shares issued in this exchange relied on the exemption from registration provided by Section 3(a)(9) of the Securities Act.
Highbridge Capital Management reported beneficial ownership of 466,667 shares of Matinas BioPharma Holdings common stock, representing 8.4% of the outstanding class based on 5,086,985 shares outstanding. The reported shares are issuable upon exercise of warrants held by Highbridge Funds and are held on behalf of those funds, with Highbridge Tactical Credit Master Fund, L.P. identified as having rights to more than 5% of the class. The filing clarifies that these securities were acquired and are held in the ordinary course of business and not for the purpose of changing control.
Matinas BioPharma Holdings, Inc. (MTNB) filed an 8-K (Item 5.03) reporting a Certificate of Amendment that doubles its authorized common stock to 500 million shares, up from 250 million. The amendment was approved at the 23 Jun 2025 annual meeting and became effective upon filing with Delaware on 6 Aug 2025.
No shares were issued and no financial statements accompanied the filing. The increased authorization gives the company added flexibility to raise capital, fund strategic transactions or expand equity-based compensation plans. However, future issuances could dilute existing shareholders and pressure per-share metrics. Investors should track subsequent financings or option grants that may utilize the newly authorized shares.
Matinas BioPharma Holdings, Inc. (MTNB) has filed a Form S-8 with the SEC on 23 June 2025 to register securities issuable under its new 2025 Equity Incentive Plan. The filing designates the company as a non-accelerated filer and smaller reporting company. Plan information required by Section 10(a) is omitted from this registration statement and will be provided directly to eligible service providers in accordance with Rule 428.
The company incorporates by reference its recent SEC filings, including: (a) the Form 10-K for the year ended 31 December 2024 (filed 15 April 2025); (b) the Form 10-Q for the quarter ended 31 March 2025 (filed 15 May 2025); (c) eleven Form 8-K filings between 10 January and 23 June 2025; and (d) the description of its common stock contained in its Form 8-A (as updated).
Standard undertakings are provided to file post-effective amendments for material changes, and the company reiterates Delaware General Corporation Law (DGCL) indemnification provisions for directors and officers. Exhibits will be listed in the Exhibit Index (not included in the excerpt). Jerome D. Jabbour, Chief Executive Officer, is named as the agent for service, with Lowenstein Sandler LLP serving as counsel.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) filed an 8-K summarizing the results of its 23 June 2025 Annual Meeting. Key outcomes were:
- 2025 Equity Incentive Plan approved – 5.39 m votes for, 0.28 m against, 0.02 m abstain; 1.81 m broker non-votes. The plan is now effective and replaces/expands prior equity programs.
- Reverse stock split authority – Shareholders authorized the Board to effect up to two reverse splits within a 1-for-2 to 1-for-199 ratio over two years (6.94 m for, 0.54 m against).
- Authorized share increase – The Charter will be amended to raise common shares from 250 m to 500 m (6.91 m for, 0.57 m against).
- Director slate re-elected – All five nominees received ~5.65 m votes each; no nominee received more than 1% withholds.
- Say-on-pay approved – Executive compensation supported by 95.3% of votes cast.
The additional share authorization and broad reverse-split range give the Board considerable flexibility to manage listing compliance, future financings and potential M&A, but could also result in material dilution or a sharply reduced share count if a high-ratio split is executed. The 2025 Plan increases equity compensation capacity, aligning management incentives but adding potential overhang. No immediate financial impact was disclosed.